Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02949960 | DMT210 Topical Gel in the Treatment of Atopic Dermatitis | PHASE2 | COMPLETED | 19 | — | — | Oct 1, 2016 | Jul 14, 2017 | Apr 18, 2018 | 2 | United States |
Change from baseline in ADSI score between Vehicle and 5% gel
| Arm | Type | Description |
|---|---|---|
| DMT210 Topical Gel | EXPERIMENTAL | DMT210 Topical Gel 5% applied to target lesion twice daily |
| Vehicle Control | PLACEBO_COMPARATOR | Topical Gel vehicle applied to target lesion twice daily |
| Name | Type | Description |
|---|---|---|
| DMT210 Topical Gel | DRUG | DMT210 Topical Aqueous Gel 5% applied twice daily |
| Vehicle Control | DRUG | Topical Vehicle Gel applied twice daily |
Inclusion Criteria: * Male or female 12 years or older * Patient has chronic, stable AD that has been present for at least 3 months with 5-35% (inclusive) BSA (Body Surface Area) of AD involvement * Patient has two analogous, Target Lesions; one lesion within each of the two Treatment Areas * Patie...